novo nordisk semaglutide patent Settles Ozempic Case Novo Nordisk drops patent suit

Learn more in our expert roundup of the best low-cost online weight-loss clinics

Always seek the guidance of a licensed medical professional before starting, changing, or stopping any medical treatment, including the use of GLP-1 medications such as semaglutide

Effectiveness in real-word of once weekly semaglutide in people with type 2 diabetes glucagon-like peptide receptor agonists nave or switchers from other glucagon-like peptide receptor agonists: results from a retrospective observational Umbria Study

June 26th, 2024: Study reveals GLP-1 drugs may cause bone density loss without exercise A recent study from the University of Copenhagen raises new concerns about GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, highlighting potential bone density loss